Medical Care

Global Anti-VEGF Therapies Market Research Report 2025

This report aims to provide a comprehensive presentation of the global market for Anti-VEGF Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGF Therapies.
The Anti-VEGF Therapies market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Anti-VEGF Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-VEGF Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Eli Lilly
Pfizer
Regeneron Pharmaceuticals
Novartis
Alphamab Oncology
Chengdu Kanghong Pharmaceutical
Segment by Type
Bevacizumab
Ramucirumab
Ranibizumab
Aflibercept
Conbercept
Other
Segment by Application
Hospitals
Clinics
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-VEGF Therapies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-VEGF Therapies Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Bevacizumab
1.2.3 Ramucirumab
1.2.4 Ranibizumab
1.2.5 Aflibercept
1.2.6 Conbercept
1.2.7 Other
1.3 Market by Application
1.3.1 Global Anti-VEGF Therapies Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-VEGF Therapies Market Perspective (2020-2031)
2.2 Global Anti-VEGF Therapies Growth Trends by Region
2.2.1 Global Anti-VEGF Therapies Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Anti-VEGF Therapies Historic Market Size by Region (2020-2025)
2.2.3 Anti-VEGF Therapies Forecasted Market Size by Region (2026-2031)
2.3 Anti-VEGF Therapies Market Dynamics
2.3.1 Anti-VEGF Therapies Industry Trends
2.3.2 Anti-VEGF Therapies Market Drivers
2.3.3 Anti-VEGF Therapies Market Challenges
2.3.4 Anti-VEGF Therapies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-VEGF Therapies Players by Revenue
3.1.1 Global Top Anti-VEGF Therapies Players by Revenue (2020-2025)
3.1.2 Global Anti-VEGF Therapies Revenue Market Share by Players (2020-2025)
3.2 Global Anti-VEGF Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Anti-VEGF Therapies Revenue
3.4 Global Anti-VEGF Therapies Market Concentration Ratio
3.4.1 Global Anti-VEGF Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-VEGF Therapies Revenue in 2024
3.5 Global Key Players of Anti-VEGF Therapies Head office and Area Served
3.6 Global Key Players of Anti-VEGF Therapies, Product and Application
3.7 Global Key Players of Anti-VEGF Therapies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-VEGF Therapies Breakdown Data by Type
4.1 Global Anti-VEGF Therapies Historic Market Size by Type (2020-2025)
4.2 Global Anti-VEGF Therapies Forecasted Market Size by Type (2026-2031)
5 Anti-VEGF Therapies Breakdown Data by Application
5.1 Global Anti-VEGF Therapies Historic Market Size by Application (2020-2025)
5.2 Global Anti-VEGF Therapies Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Anti-VEGF Therapies Market Size (2020-2031)
6.2 North America Anti-VEGF Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Anti-VEGF Therapies Market Size by Country (2020-2025)
6.4 North America Anti-VEGF Therapies Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-VEGF Therapies Market Size (2020-2031)
7.2 Europe Anti-VEGF Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Anti-VEGF Therapies Market Size by Country (2020-2025)
7.4 Europe Anti-VEGF Therapies Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-VEGF Therapies Market Size (2020-2031)
8.2 Asia-Pacific Anti-VEGF Therapies Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Anti-VEGF Therapies Market Size by Region (2020-2025)
8.4 Asia-Pacific Anti-VEGF Therapies Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-VEGF Therapies Market Size (2020-2031)
9.2 Latin America Anti-VEGF Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Anti-VEGF Therapies Market Size by Country (2020-2025)
9.4 Latin America Anti-VEGF Therapies Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-VEGF Therapies Market Size (2020-2031)
10.2 Middle East & Africa Anti-VEGF Therapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Anti-VEGF Therapies Market Size by Country (2020-2025)
10.4 Middle East & Africa Anti-VEGF Therapies Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Anti-VEGF Therapies Introduction
11.1.4 Roche Revenue in Anti-VEGF Therapies Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Anti-VEGF Therapies Introduction
11.2.4 Eli Lilly Revenue in Anti-VEGF Therapies Business (2020-2025)
11.2.5 Eli Lilly Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Anti-VEGF Therapies Introduction
11.3.4 Pfizer Revenue in Anti-VEGF Therapies Business (2020-2025)
11.3.5 Pfizer Recent Development
11.4 Regeneron Pharmaceuticals
11.4.1 Regeneron Pharmaceuticals Company Details
11.4.2 Regeneron Pharmaceuticals Business Overview
11.4.3 Regeneron Pharmaceuticals Anti-VEGF Therapies Introduction
11.4.4 Regeneron Pharmaceuticals Revenue in Anti-VEGF Therapies Business (2020-2025)
11.4.5 Regeneron Pharmaceuticals Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Anti-VEGF Therapies Introduction
11.5.4 Novartis Revenue in Anti-VEGF Therapies Business (2020-2025)
11.5.5 Novartis Recent Development
11.6 Alphamab Oncology
11.6.1 Alphamab Oncology Company Details
11.6.2 Alphamab Oncology Business Overview
11.6.3 Alphamab Oncology Anti-VEGF Therapies Introduction
11.6.4 Alphamab Oncology Revenue in Anti-VEGF Therapies Business (2020-2025)
11.6.5 Alphamab Oncology Recent Development
11.7 Chengdu Kanghong Pharmaceutical
11.7.1 Chengdu Kanghong Pharmaceutical Company Details
11.7.2 Chengdu Kanghong Pharmaceutical Business Overview
11.7.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Therapies Introduction
11.7.4 Chengdu Kanghong Pharmaceutical Revenue in Anti-VEGF Therapies Business (2020-2025)
11.7.5 Chengdu Kanghong Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Anti-VEGF Therapies Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Bevacizumab
Table 3. Key Players of Ramucirumab
Table 4. Key Players of Ranibizumab
Table 5. Key Players of Aflibercept
Table 6. Key Players of Conbercept
Table 7. Key Players of Other
Table 8. Global Anti-VEGF Therapies Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Anti-VEGF Therapies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Anti-VEGF Therapies Market Size by Region (2020-2025) & (US$ Million)
Table 11. Global Anti-VEGF Therapies Market Share by Region (2020-2025)
Table 12. Global Anti-VEGF Therapies Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 13. Global Anti-VEGF Therapies Market Share by Region (2026-2031)
Table 14. Anti-VEGF Therapies Market Trends
Table 15. Anti-VEGF Therapies Market Drivers
Table 16. Anti-VEGF Therapies Market Challenges
Table 17. Anti-VEGF Therapies Market Restraints
Table 18. Global Anti-VEGF Therapies Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Anti-VEGF Therapies Market Share by Players (2020-2025)
Table 20. Global Top Anti-VEGF Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Therapies as of 2024)
Table 21. Ranking of Global Top Anti-VEGF Therapies Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Anti-VEGF Therapies Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Anti-VEGF Therapies, Headquarters and Area Served
Table 24. Global Key Players of Anti-VEGF Therapies, Product and Application
Table 25. Global Key Players of Anti-VEGF Therapies, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Anti-VEGF Therapies Market Size by Type (2020-2025) & (US$ Million)
Table 28. Global Anti-VEGF Therapies Revenue Market Share by Type (2020-2025)
Table 29. Global Anti-VEGF Therapies Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 30. Global Anti-VEGF Therapies Revenue Market Share by Type (2026-2031)
Table 31. Global Anti-VEGF Therapies Market Size by Application (2020-2025) & (US$ Million)
Table 32. Global Anti-VEGF Therapies Revenue Market Share by Application (2020-2025)
Table 33. Global Anti-VEGF Therapies Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 34. Global Anti-VEGF Therapies Revenue Market Share by Application (2026-2031)
Table 35. North America Anti-VEGF Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. North America Anti-VEGF Therapies Market Size by Country (2020-2025) & (US$ Million)
Table 37. North America Anti-VEGF Therapies Market Size by Country (2026-2031) & (US$ Million)
Table 38. Europe Anti-VEGF Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 39. Europe Anti-VEGF Therapies Market Size by Country (2020-2025) & (US$ Million)
Table 40. Europe Anti-VEGF Therapies Market Size by Country (2026-2031) & (US$ Million)
Table 41. Asia-Pacific Anti-VEGF Therapies Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 42. Asia-Pacific Anti-VEGF Therapies Market Size by Region (2020-2025) & (US$ Million)
Table 43. Asia-Pacific Anti-VEGF Therapies Market Size by Region (2026-2031) & (US$ Million)
Table 44. Latin America Anti-VEGF Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Latin America Anti-VEGF Therapies Market Size by Country (2020-2025) & (US$ Million)
Table 46. Latin America Anti-VEGF Therapies Market Size by Country (2026-2031) & (US$ Million)
Table 47. Middle East & Africa Anti-VEGF Therapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 48. Middle East & Africa Anti-VEGF Therapies Market Size by Country (2020-2025) & (US$ Million)
Table 49. Middle East & Africa Anti-VEGF Therapies Market Size by Country (2026-2031) & (US$ Million)
Table 50. Roche Company Details
Table 51. Roche Business Overview
Table 52. Roche Anti-VEGF Therapies Product
Table 53. Roche Revenue in Anti-VEGF Therapies Business (2020-2025) & (US$ Million)
Table 54. Roche Recent Development
Table 55. Eli Lilly Company Details
Table 56. Eli Lilly Business Overview
Table 57. Eli Lilly Anti-VEGF Therapies Product
Table 58. Eli Lilly Revenue in Anti-VEGF Therapies Business (2020-2025) & (US$ Million)
Table 59. Eli Lilly Recent Development
Table 60. Pfizer Company Details
Table 61. Pfizer Business Overview
Table 62. Pfizer Anti-VEGF Therapies Product
Table 63. Pfizer Revenue in Anti-VEGF Therapies Business (2020-2025) & (US$ Million)
Table 64. Pfizer Recent Development
Table 65. Regeneron Pharmaceuticals Company Details
Table 66. Regeneron Pharmaceuticals Business Overview
Table 67. Regeneron Pharmaceuticals Anti-VEGF Therapies Product
Table 68. Regeneron Pharmaceuticals Revenue in Anti-VEGF Therapies Business (2020-2025) & (US$ Million)
Table 69. Regeneron Pharmaceuticals Recent Development
Table 70. Novartis Company Details
Table 71. Novartis Business Overview
Table 72. Novartis Anti-VEGF Therapies Product
Table 73. Novartis Revenue in Anti-VEGF Therapies Business (2020-2025) & (US$ Million)
Table 74. Novartis Recent Development
Table 75. Alphamab Oncology Company Details
Table 76. Alphamab Oncology Business Overview
Table 77. Alphamab Oncology Anti-VEGF Therapies Product
Table 78. Alphamab Oncology Revenue in Anti-VEGF Therapies Business (2020-2025) & (US$ Million)
Table 79. Alphamab Oncology Recent Development
Table 80. Chengdu Kanghong Pharmaceutical Company Details
Table 81. Chengdu Kanghong Pharmaceutical Business Overview
Table 82. Chengdu Kanghong Pharmaceutical Anti-VEGF Therapies Product
Table 83. Chengdu Kanghong Pharmaceutical Revenue in Anti-VEGF Therapies Business (2020-2025) & (US$ Million)
Table 84. Chengdu Kanghong Pharmaceutical Recent Development
Table 85. Research Programs/Design for This Report
Table 86. Key Data Information from Secondary Sources
Table 87. Key Data Information from Primary Sources
Table 88. Authors List of This Report


List of Figures
Figure 1. Anti-VEGF Therapies Picture
Figure 2. Global Anti-VEGF Therapies Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Anti-VEGF Therapies Market Share by Type: 2024 VS 2031
Figure 4. Bevacizumab Features
Figure 5. Ramucirumab Features
Figure 6. Ranibizumab Features
Figure 7. Aflibercept Features
Figure 8. Conbercept Features
Figure 9. Other Features
Figure 10. Global Anti-VEGF Therapies Market Size by Application (2020-2031) & (US$ Million)
Figure 11. Global Anti-VEGF Therapies Market Share by Application: 2024 VS 2031
Figure 12. Hospitals Case Studies
Figure 13. Clinics Case Studies
Figure 14. Anti-VEGF Therapies Report Years Considered
Figure 15. Global Anti-VEGF Therapies Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Anti-VEGF Therapies Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Anti-VEGF Therapies Market Share by Region: 2024 VS 2031
Figure 18. Global Anti-VEGF Therapies Market Share by Players in 2024
Figure 19. Global Top Anti-VEGF Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Therapies as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Anti-VEGF Therapies Revenue in 2024
Figure 21. North America Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Anti-VEGF Therapies Market Share by Country (2020-2031)
Figure 23. United States Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Anti-VEGF Therapies Market Share by Country (2020-2031)
Figure 27. Germany Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Anti-VEGF Therapies Market Share by Region (2020-2031)
Figure 35. China Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Anti-VEGF Therapies Market Share by Country (2020-2031)
Figure 43. Mexico Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Anti-VEGF Therapies Market Share by Country (2020-2031)
Figure 47. Turkey Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Anti-VEGF Therapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Roche Revenue Growth Rate in Anti-VEGF Therapies Business (2020-2025)
Figure 51. Eli Lilly Revenue Growth Rate in Anti-VEGF Therapies Business (2020-2025)
Figure 52. Pfizer Revenue Growth Rate in Anti-VEGF Therapies Business (2020-2025)
Figure 53. Regeneron Pharmaceuticals Revenue Growth Rate in Anti-VEGF Therapies Business (2020-2025)
Figure 54. Novartis Revenue Growth Rate in Anti-VEGF Therapies Business (2020-2025)
Figure 55. Alphamab Oncology Revenue Growth Rate in Anti-VEGF Therapies Business (2020-2025)
Figure 56. Chengdu Kanghong Pharmaceutical Revenue Growth Rate in Anti-VEGF Therapies Business (2020-2025)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies